Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 42

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 42
---
 reverse stock split.

    F-5

NOTE
2: SIGNIFICANT ACCOUNTING POLICIES

Basis
of presentation

The
unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States of America (“US GAAP”) and SEC Regulation S-X Article 10 for interim financial statements.
Accordingly, they do not contain all the information and notes required by US GAAP for annual financial statements. In the opinion of
management, these unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring
adjustments, necessary for a fair statement of the Company’s consolidated financial position as of September 30, 2025, and the
consolidated results of operations and changes in stockholders’ equity for the three- and nine-month periods ended September 30,
2025 and 2024 and cash flows for the nine-month periods ended September 30, 2025 and 2024.

These
unaudited  condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with
the SEC on March 13, 2025. The consolidated balance sheet data as of December 31, 2024, included in these unaudited condensed consolidated
financial statements was derived from the audited financial statements for the year ended December 31, 2024, but does not include all
disclosures required by US GAAP for annual financial statements.

The
results for the nine-month period ended September 30, 2025, are not necessarily indicative of the results expected for the year ending
December 31, 2025.

Principles
of consolidation

The
unaudited condensed consolidated financial statements include the accounts of Indaptus Therapeutics, Inc. and its subsidiaries. Intercompany
balances and transactions have been eliminated upon consolidation.

Use
of estimates

The
preparation of the unaudited condensed consolidated financial statements in accordance with US GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the
date of the financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates
relate to the determination of the fair value of stock-based compensation and the determination of period-end obligations to certain